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AbstrAct 
background Smoking cessation was examined among 
a subset of current smokers who were high-risk partici-
pants in the UK Lung Cancer Screening (UKLS) pilot trial 
of low-dose CT screening.
Methods High-risk individuals aged 50–75 years who 
completed baseline questionnaires were randomised to 
CT screening (intervention) or usual care (no screening 
control). Smoking habit was determined at baseline 
using self-report. Smokers were asked whether they 
had quit smoking since joining UKLS at short-term 
follow-up (2 weeks after baseline scan results or control 
assignment) and longer-term follow-up (up to 2 years 
after recruitment). Intention to treat (ITT) regression 
analyses were undertaken, adjusting for baseline lung 
cancer distress, trial site and sociodemographic variables.
results Of a total of 4055 individuals randomised to 
CT screening or control, 1546 were baseline smokers 
(787 control, 759 intervention). Smoking cessation rates 
were 5% (control n=36/786) versus 10% (intervention 
n=75/758) at 2 weeks and 10% (control n=79/775) 
versus 15% (intervention n=115/749) at up to 2 years 
follow-up. ITT analyses indicated that the odds of 
quitting among screened participants were significantly 
higher in the short term (adjusted OR (aOR) 2.38, 
95% CI 1.56 to 3.64, p<0.001) and longer term (aOR 
1.60, 95% CI 1.17 to 2.18, p=0.003) compared with 
control. Intervention participants who needed additional 
clinical investigation were more likely to quit in the 
longer term than the control group (aOR 2.29, 95% CI 
1.62 to 3.22, p=0.007) and those receiving a negative 
result (aOR 2.43, 95% CI 1.54 to 3.84, p<0.001).
conclusion CT lung cancer screening for high-risk 
participants offers a teachable moment for smoking 
cessation, especially among those who receive a positive 
scan result. Further behavioural research is needed to 
evaluate optimal strategies for integrating smoking 
cessation intervention with stratified lung cancer 
screening.
IntroductIon
Smoking is the leading cause of preventable 
morbidity and premature mortality worldwide.1 
In the UK, an estimated 86% of lung cancer cases 
are attributable to smoking.2 The prevalence of 
cigarette smoking in the UK remained relatively 
stable between 2006 and 2014 at approximately 
10 million adults (~20%),3 and although these 
rates are much lower than those of the 1970s, this 
declining trend has begun to plateau.4 The associa-
tion between cigarette smoking and socioeconomic 
group is well established, with higher smoking rates 
among people living in more deprived areas.5
Trials have been undertaken to ascertain the 
effectiveness of low-dose CT screening for the 
earlier detection of lung cancer in high-risk groups 
including smokers.6–9 The impact of CT lung 
screening on smoking cessation and abstinence 
has been examined in response to concerns that 
taking part in lung screening may offer a ‘license to 
smoke’, especially for smokers who receive favour-
able screening results.10 Evidence from controlled 
trials, however, suggests that participating in lung 
screening significantly increases smoking cessation 
rates overall compared with the general popula-
tion, and that receiving a positive CT screening 
result may provide an additional cue to action in 
prompting cessation. The Danish Lung Cancer 
Screening Trial (DLCST) reported smoking cessa-
tion rates of almost 12% in both trial arms at 1 year 
follow-up, compared with the Danish population 
rate of 4%.11 Quit rate was significantly higher in 
smokers who had a positive CT result that required 
repeat scans.11 In the Dutch-Belgian NELSON trial, 
the overall quit rate at 2 years follow-up was 16.6% 
compared with a background population rate of 
3–7%. Although a lower prolonged abstinence rate 
was observed in the screened arm (14.5%) versus 
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Key messages
What is the key question?
What is the effect on smoking cessation of taking 
part in the UK randomised pilot trial of low dose 
CT lung screening?
What is the bottom line?
CT lung cancer screening does not appear to 
falsely reassure smokers or reduce their motivation 
to stop smoking.
Why read on?
For clinicians and policy makers who are consid-
ering implementation of risk-stratified lung cancer 
screening, this study adds to evidence suggesting 
that integrating CT screening with evidence-based 
smoking cessation interventions could prompt quit-
ting in motivated high-risk smokers.
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control (19.1%), this effect disappeared following intention to 
treat analysis, suggesting an overall positive effect of trial partic-
ipation.12 A non-significant trend towards increased smoking 
cessation was seen in those with multiple indeterminate screening 
results.13 The US National Lung Screening Trial (NLST)14 found 
that, compared with normal lung screening results, receiving any 
screen-detected abnormality significantly reduced the proba-
bility of continued smoking.
In addition to the moderating effect of lung screening results, 
sociodemographic predictors of increased likelihood of smoking 
cessation have been observed in previous lung cancer screening 
studies. These have included older age,11 14 15 higher socioeco-
nomic group,14 higher education,12 being married14 and lower 
nicotine dependency.11 14 In addition, participants with higher 
levels of concern about lung cancer and greater perceived 
benefits of stopping smoking,10 and those who intend to stop 
smoking,11 12 are more likely to quit in the context of lung cancer 
screening.
The UK Lung Cancer Screening (UKLS) pilot trial is the first 
to assess the feasibility, cost-effectiveness and psychosocial 
impact of lung cancer screening using a single low-dose CT 
screen versus no screening in a UK high-risk population.9 16 
The current study builds on previous UKLS reports by exam-
ining the behavioural effects of trial participation and modi-
fying variables on smoking cessation at short-term and long-
term follow-up. It was expected that screened participants, and 
in particular those receiving positive CT results, would be more 
likely to report quitting compared with control arm partici-
pants.
Methods
Participants and procedures
A random sample of 2 47 354 individuals aged 50–75 years 
residing in six recruitment areas in the UK (Liverpool, Knowsley 
and Sefton; Cambridgeshire, Peterborough and Bedfordshire) 
were sent trial information packs that included a self-report 
questionnaire regarding lung cancer risk factors. From the ques-
tionnaire responders, 8729 patients were identified as at high 
risk of lung cancer (≥5% over 5 years) using the Liverpool Lung 
Project (LLPv2) risk prediction model which includes age, sex, 
family history of lung cancer, smoking duration, personal history 
of other cancers and non-malignant respiratory diseases, and 
exposure to asbestos.9 Characteristics of trial non-participants 
are reported elsewhere.17 18
Following completion of a second questionnaire to identify 
trial eligibility, those meeting the criteria were invited to attend 
their local recruitment centre in Liverpool or Cambridge (trial 
sites). High-risk individuals who gave informed written consent 
were randomised on a 1:1 ratio to the intervention (screening) 
or control arms. Randomisation used unique random personal 
ID codes and computer-generated sequencing for allocation 
concealment.9 Participants who self-reported smoking in the 
first questionnaire were eligible for inclusion in the current 
analyses. Participants in both trial arms were offered standard 
smoking cessation advice leaflets and given a list of local NHS 
Stop Smoking services pre-randomisation.
Participants completed a touchscreen questionnaire that 
included baseline psychosocial measures (T0). A second psycho-
social questionnaire (T1) was sent approximately 2 weeks after 
receiving either a letter of assignment to the control group or a 
baseline CT scan result letter (intervention arm). T2 psychoso-
cial questionnaires were sent in a single mailshot during January 
2014.
Measures
Smoking status was calculated at T0 based on self-report data 
within the first UKLS questionnaire. Participants were catego-
rised into current smokers, ex-smokers and never smokers.
Smoking cessation was assessed using self-report at T1 and T2. 
Participants were asked whether they had quit smoking since 
joining UKLS, with response options ‘yes’, ‘no’, ‘no but I intend 
to quit smoking within the next 6 months’, ‘not applicable’ (ie, 
not a smoker at baseline). Participants who responded ‘no’ or 
‘no, but intend to quit’ were categorised as non-quitters. Those 
who responded ‘not applicable’ or who returned the question-
naire but missed out the smoking cessation question were cate-
gorised as non-completers.
Lung cancer distress was measured using six items adapted 
from Lerman et al19 and Watson et al20 to assess the frequency of 
lung cancer-related thoughts and their impact on mood and daily 
functioning. Total score range was 6–24, with a score above 12.5 
corresponding to a clinically significant threshold score on the 
General Health Questionnaire-28.21
Sociodemographic variables (age and gender) were obtained 
from medical records. Socioeconomic group was measured 
using Index of Multiple Deprivation (IMD) ranks calculated 
from postcodes and categorised into standard deprivation quin-
tiles (quintile 1 = most deprived, quintile 5 = least deprived). 
Marital group and experience of lung cancer (self and/or close 
others) were included in the T0 questionnaire.
screening results
Baseline CT scan results in the intervention arm included nega-
tive (normal) results, those requiring a repeat scan in 3 or 12 
months, those requiring referral to the multidisciplinary team 
due to a major lung abnormality and significant incidental find-
ings (such as aortic aneurysms and pneumonia but with no find-
ings suspicious for lung cancer).
statistical analysis
Analyses were conducted using Stata V.14. Following descriptive 
analyses to examine baseline equivalence of trial arms, the base-
line characteristics of smokers who did and did not complete 
follow-up questionnaires were compared using chi-squared 
and independent t-tests. Participants who did not answer the 
smoking cessation question at T1 or T2 were imputed as smokers 
and included in the primary analysis of intervention effect using 
the intention to treat (ITT) population, in accordance with 
the Russell Standard for reporting smoking cessation trials.22 
Complete case analyses were also conducted using univari-
able logistic regression models fitted to the smoking cessation 
outcome data at T1 and T2 independently with an inverse proba-
bility weighting.23 Additionally, as a secondary analysis to adjust 
for confounders, multivariable logistic regression models were 
fitted to evaluate the impact of trial allocation on smoking cessa-
tion at T1 and T2 adjusting for T0 (baseline) lung cancer distress, 
sociodemographic factors (gender, age group, marital group, 
deprivation quintile, experience of lung cancer) and trial site.16 
Odds ratios (ORs) and adjusted ORs (aORs) with 95% CIs and p 
values are presented. Due to multiple testing, p<0.01 was used 
to denote statistical significance.
To investigate the effect of the baseline scan result on smoking 
cessation, we summarised intervention arm participants into 
those who had a scan leading to additional clinical investiga-
tion (including repeat scan, major abnormality and incidental 
findings) and those receiving a negative result (ie, not requiring 
further investigation). Participants randomised to the control 
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group were used as the reference category in order to reflect 
current practice. The impact of additional clinical investigation 
on smoking cessation at T1 and T2 was analysed using univariable 
and multivariable logistic regression in the ITT and complete 
case populations. Lung cancer distress, sociodemographic factors 
and trial site were included in multivariable analysis.
Further subgroup analyses were carried out within the inter-
vention arm only, involving additional univariable regression 
analyses to examine T1 and T2 smoking cessation in those 
receiving additional clinical investigation compared with a nega-
tive result as the reference category. We carried out this analysis 
to reflect a potential national policy where participants receive 
routine lung screening.
resuLts
trial participation
In total, 4061 individuals (5% of 75 958 responders to the risk 
questionnaire; 47% of all high-risk positive responders) attended 
the recruitment clinic and consented to participate.24 As shown 
in figure 1, 4055 trial participants were randomised (n=2028 
CT intervention, n=2027 control). In the subset of smokers who 
were included in the study, 759 (49%) were in the intervention 
arm and 787 (51%) were in the control arm. Characteristics of 
the smokers split by trial arm are provided in table 1, and indi-
cate equivalence of groups in baseline sociodemographic and 
psychological characteristics.
Among smokers who were sent questionnaires, the comple-
tion rate at T1 (2 weeks follow-up) was n=527/758 (70%) for 
the intervention arm and n=479/786 (61%) for the control 
arm, giving a total T1 sample of n=1006. The completion rate 
at T2 (up to 2 years follow-up) was n=488/749 (65%) for the 
screening arm and n=377/775 (49%) for the control arm (total 
T2 n=865) (see figure 1).
Factors associated with non-completion
Baseline smokers in the control arm and those with experience of 
lung cancer were significantly less likely than those in the inter-
vention arm to complete T1 questionnaires (see online Supple-
mentary table 1). Trial site, age, gender, marital group, depri-
vation and T0 lung cancer distress were not statistically signifi-
cantly associated with T1 completion.
T2 questionnaire completion was significantly lower among 
baseline smokers in the control arm and those recruited at the 
Liverpool site, in the most deprived quintile and with experience 
of lung cancer. Age, marital group, gender and baseline distress 
were not statistically significantly associated with T2 completion 
(see online Supplementary table 2).
effect of trial allocation on t1 and t2 smoking cessation
Primary ITT and complete case analyses are summarised in 
table 2. After imputing missing data as smokers in the primary 
ITT analysis, within the screening arm 75/758 (10%) quit 
smoking at T1 and there were 527 eligible responders. In the 
control arm, 36/786 (5%) participants quit smoking at T1 and 
there were 479 eligible responders. T1 smoking cessation was 
statistically significantly higher in screened individuals compared 
with controls (OR 2.29, 95% CI 1.52 to 3.45, p<0.001), and 
remained statistically significant after adjusting for T0 distress and 
all other covariates (aOR 2.38, 95% CI 1.56 to 3.64, p=0.001). 
Complete case analysis confirmed that T1 smoking cessation was 
statistically significantly higher in the intervention group (aOR 
2.09, 95% CI 1.36 to 3.23, p<0.001). Effects of covariates on T1 
smoking cessation are included in online  Supplementary table 
3 (ITT analysis).
At T2, 115/749 (15%) participants quit smoking and 488 
returned the questionnaire in the screening arm. There were 
79/775 (10%) individuals who quit in the control arm and 377 
eligible responses at T2 (see table 2). The effect of trial arm on 
quitting smoking at T2 was statistically significant in the crude 
ITT analysis (OR 1.60, 95% CI 1.18 to 2.17, p=0.003) and 
after adjusting for covariates (aOR 1.60, 95% CI 1.17 to 2.18, 
p=0.003). In complete case analysis, the difference in cessation 
rate between the intervention and control groups at T2 was not 
statistically significant (aOR 1.16, 95% CI 0.65 to 1.33, p=0.36), 
therefore these findings should be interpreted with caution. The 
influence of covariates on longer term smoking outcomes in ITT 
analysis are included in online Supplementary table 4.
Impact of additional clinical investigation on smoking cessa-
tion
As shown in table 3, T1 smoking cessation was reported by 16% 
(48/299) of participants who had additional clinical investiga-
tion following the baseline scan result and 11% (26/227) who 
received a negative result. These were both compared with 8% 
(36/479) who reported T1 smoking cessation in the control 
group. Using the imputed population, the impact of needing 
additional clinical investigation on T1 smoking cessation was 
statistically significant in univariable (OR 2.72, 95% CI 1.73 to 
4.26, p<0.001) and multivariable (aOR 2.85, 95% CI 1.79 to 
4.53, p<0.001) analysis. The effect of receiving a negative result 
on T1 smoking cessation was not significant at the 1% signifi-
cance level in the univariable (OR 1.73, 95% CI 1.02 to 2.91, 
p=0.04) and multivariable (aOR 1.78, 95% CI 1.04 to 3.05, 
p=0.03) analysis. Similar findings were observed in complete 
case analysis for both T1 comparisons.
At T2, 30% (83/275) of participants who received additional 
clinical investigation following the baseline scan result and 15% 
(32/212) who had negative results reported cessation. These 
were compared with 21% (79/377) in the control group who 
reported quitting at T2. There was a statistically significant effect 
of additional clinical investigation on T2 smoking cessation 
in univariable (OR 2.24, 95% CI 1.60 to 3.14, p<0.001) and 
multivariable (aOR 2.29, 95% CI 1.62 to 3.22, p<0.001) ITT 
analysis. The effect of a negative result on T2 smoking cessa-
tion was not significant in univariable (OR 0.92, 95% CI 0.60 
to 1.42, p=0.71) and multivariable (aOR 0.90, 95% CI 0.58 to 
1.40, p=0.64) analysis; however, caution is needed when inter-
preting these findings. Similar results were observed in complete 
case analysis (see table 3).
subgroup analyses in the intervention group only
At T1 there was no statistically significant effect of needing addi-
tional clinical investigation on smoking cessation compared with 
receiving a negative result (aOR 1.60, 95% CI 0.96 to 2.67, 
p=0.07). At T2 there was a clear effect on smoking cessation of 
additional clinical investigation compared with a negative result 
(aOR 2.57, 95% CI 1.64 to 4.03, p<0.001). Similar results were 
found in complete case analysis (results not shown).
dIscussIon
Tobacco control is the major primary prevention option for lung 
cancer. The present study is the first to report the behavioural 
impact of CT screening in a UK high-risk population, and 
confirms the findings of previous trials that lung cancer screening 
does not falsely reassure smokers or reduce their motivation to 
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Figure 1 Trial CONSORT (Consolidated Standards of Reporting Trials) diagram.
Lung cancer
stop smoking. Using the imputed population, the short-term 
quit rate of 10% among screened participants was higher than 
the background cessation rate in the general UK population 
(4%),25 26 with the longer term quit rate of 15% similar to that 
reported in the Dutch-Belgian NELSON trial12 and higher than 
the DLCST trial.11 Participating in the UKLS appeared to prompt 
smoking cessation overall, with a differential and positive effect 
of lung screening at short-term and longer-term follow-up. 
While a degree of caution is needed due to imputation of 
missing responders as smokers,22 the present findings indicate 
that smoking cessation was higher in the intervention arm and 
that engaging in CT lung cancer screening increased the likeli-
hood of stopping smoking in the longer term. Despite concerns 
about a negative lung screen offering a ‘license to smoke’,10 there 
was no evidence that UKLS screening participants who received 
an all-clear CT result were less likely to quit. Analysis indicated 
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table 1 Sample characteristics
not recorded (missing) ct scan (n=759) n (%) or mean (sd) control (n=787) n (%) or mean (sd)
Site Liverpool 425 (56%) 431 (55%)
Cambridge 334 (44%) 356 (45%)
Age (years) 66.7 (4.10) 66.3 (4.3)
Gender Male 532 (70%) 551 (70%)
Female 227 (30%) 236 (30%)
Marital group Married/cohabiting 3 502 (66%) 519 (66%)
Not married/cohabiting 256 (34%) 266 (34%)
IMD Quintile 1 (most deprived) 265 (35%) 265 (34%)
Quintile 2 93 (12%) 97 (12%)
Quintile 3 128 (17%) 125 (16%)
Quintile 4 108 (14%) 136 (17%)
Quintile 5 (least deprived) 165 (22%) 164 (21%)
Lung cancer 
experience
No 4 442 (58%) 433 (55%)
Yes 315 (42%) 352 (45%)
Cancer distress (T0)* 2.23 (0.30)
9.86 (3.08)
2.24 (0.30)
9.72 (2.99)
Percentages were calculated based on available data.
*Logn scores in normal text, original scores in italics (analyses performed using logn scores).
IMD, Index of Multiple Deprivation.
table 2 Effect of trial allocation on smoking cessation at T1 (2 weeks) and T2 (2 years) follow-up
time point Analysis population
Quit smoking/total univariable
or (95% cI)
Multivariable
or‡ (95% cI)ct scan (n=759) control (n=787)
T1 (2 weeks) Primary ITT*
complete case
75/758 (10%)†
75/527 (14%)
36/786 (5%)†
36/479 (8%)
2.29 (1.52 to 3.45)
2.04 (1.34 to 3.10)
2.38 (1.56 to 3.64)
2.09 (1.36 to 3.23)
T2 (2 years) Primary ITT* complete 
case
115/749 (15%)†
115/488 (24%)
79/775 (10%)†
79/377 (21%)
1.60 (1.18 to 2.17)
1.16 (0.84 to 1.61)
1.60 (1.17 to 2.18)
1.16 (0.65 to 1.33)
*Primary intention to treat (ITT) analysis using the imputed population. Where no data were available on smoking status at follow-up, the participant was assumed to be 
smoking.
†Participants were excluded due to administrative error: T1 CT scan (n=1); T1 control (n=1); T2 CT scan (n=10); T2 control (n=12).
‡Adjusted for T0 cancer distress, recruitment site, gender, age, marital group, deprivation and experience of lung cancer.
Lung cancer
that a positive CT scan result prompted smoking cessation in the 
longer term compared with participants who were not screened 
and participants who received a negative scan, suggesting that a 
positive lung screening result may provide an additional stim-
ulus for quitting over and above that of screening participation. 
This mirrors the findings of other controlled trials including 
the DLCST11 and US NLST,14 where smokers with identified 
abnormalities were more likely to stop smoking than those with 
normal results.
The current evidence suggests that an integrated package of 
CT lung screening and smoking cessation support has the poten-
tial to expedite quitting in smokers who are motivated and 
receptive. The voluntary nature of the trial meant that smokers 
who took part were self-selected and may already have been 
contemplating quitting.27 It is difficult, therefore, to directly 
attribute smoking cessation to UKLS participation, although 
Ostroff et al10 reported that smokers who quit after CT lung 
screening ascribed their decision to screening participation. In 
the current trial we observed a marginal trend towards higher 
baseline distress in those who reported quitting in the short term 
(see supplementary materials), which suggests that experi-
encing a degree of concern about lung cancer may be necessary 
to galvanise smoking cessation. However, we did not directly 
assess baseline quit intentions, and future evaluations of CT lung 
screening would therefore benefit from examining the influence 
of both mood and smoking-related cognitions on behavioural 
outcomes.
The limitations of sample size and study design are acknowl-
edged. The UKLS trial was not specifically designed to test 
the effects of lung screening combined with smoking cessation 
support, hence the types of stop-smoking interventions accepted 
by participants were not recorded, nor were comparative data 
available on cessation rates in the Liverpool and Papworth 
regions during the life of the trial. It was not possible to ascertain 
the moderating role of nicotine dependence or biochemically 
validate self-reported smoking behaviour, therefore the current 
findings should be interpreted cautiously due to the sole use of 
self-reported cessation. Nevertheless, the present study adds 
to growing evidence that integrating CT lung screening with 
evidence-based smoking cessation interventions could prompt 
quitting in motivated high-risk smokers. While our sample was 
not sufficiently large to examine continued smoking abstinence 
in those who reported quitting at short-term follow-up, the 
NELSON trial indicated that combining low-dose CT screening 
with smoking cessation advice led to sustained abstinence.12 Most 
smokers enrolling in CT lung screening studies are motivated 
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table 3 Impact of baseline scan result on smoking cessation at T1 (2 weeks) and T2 (2 years) follow-up
baseline scan result Quit smoking total univariable or (95% cI) Multivariable or† (95% cI)
ITT analysis*
T1 Control group 36 786  Reference Reference
Negative result‡ 26 340 1.73 (1.02 to 2.91) 1.78 (1.04 to 3.05)
Additional investigation‡ 48 416 2.72 (1.73 to 4.26) 2.85 (1.79 to 4.53)
T2 Control group 79 775 Reference Reference
Negative result‡ 32 338 0.92 (0.60 to 1.42) 0.90 (0.58 to 1.40)
Additional investigation‡ 83 409 2.24 (1.60 to 3.14) 2.29 (1.62 to 3.22)
Complete case analysis
T1 Control group 36 479 Reference Reference
Negative result 26 227 1.59 (0.94 to 2.71) 1.61 (0.93 to 2.77)
Additional investigation‡ 48 299 2.35 (1.49 to 3.72) 2.46 (1.53 to 3.96)
T2 Control group 79 377 Reference Reference
Negative result 32 212 0.67 (0.43 to 1.05) 0.65 (0.41 to 1.04)
Additional investigation‡ 83 275 1.63 (1.14 to 2.33) 1.66 (1.15 to 2.39)
*Primary intention to treat (ITT) analysis using the imputed population.
†Adjusted for T0 cancer distress, recruitment site, gender, age, marital group, deprivation and experience of lung cancer.
‡One participant removed due to protocol deviation.
Lung cancer
to quit, therefore it will be critical to evaluate actual quit rates 
prompted by screening, and whether they are maintained over 
time in the context of a lung screening health service. We found 
that longer term study retention was less likely in smokers who 
were from socioeconomically deprived areas and who had expe-
rience of lung cancer. Evidence from other studies suggests that 
these high-risk groups may be deterred from lung screening due 
to fearful and fatalistic beliefs about lung cancer outcomes,28–30 
stigma and scepticism about the benefits of screening.31–33 The 
consistent association between smoking, deprivation and lower 
screening uptake is a problem for public health that must be 
addressed in future lung screening.
Implementation of a UK national lung cancer screening 
programme for high-risk groups offers opportunities for 
smoking cessation at multiple points in the screening process, 
from the initial screening invitation to CT scanning and disclo-
sure of results.10 Smoking cessation counselling combined with 
pharmacotherapy is effective,34–36 and could be successfully 
implemented in the lung screening setting.37 However, further 
behavioural research is needed to identify ways of engaging 
harder to reach smokers, and to robustly test the optimal type 
and timing of strategies for delivering stop-smoking support to 
high-risk participants. Successful integration of evidence-based 
strategies for smoking cessation with stratified lung cancer 
screening could be a prudent use of limited healthcare resources, 
translating into major health benefits for all smoking-related 
diseases.
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